Zevra Therapeutics, Inc. (ZVRA) – What Are Brokerages Thinking About This Stock?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has been assigned an average rating of “Buy” from the eleven research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $27.14.

A number of brokerages have recently weighed in on ZVRA. BTIG Research dropped their target price on Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating on the stock in a report on Monday, July 27th. Citizens Jmp upped their target price on Zevra Therapeutics from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, August 6th. Guggenheim reduced their target price on shares of Zevra Therapeutics from $24.00 to $23.00 and set a “buy” rating for the company in a research note on Friday, August 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Zevra Therapeutics in a research note on Wednesday, August 19th. Finally, Wall Street Zen raised Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th.

Insider Buying and Selling

In other Zevra Therapeutics news, Director Corey Watton sold 12,300 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $11.25, for a total transaction of $138,375.00. Following the completion of the sale, the director directly owned 1,800 shares in the company, valued at $20,250. This represents a 87.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 3.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Zevra Therapeutics

Several large investors have recently bought and sold shares of the stock. Integrated Wealth Concepts LLC acquired a new stake in shares of Zevra Therapeutics in the 2nd quarter valued at $28,000. Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new position in shares of Zevra Therapeutics in the fourth quarter valued at approximately $53,000. DGS Capital Management LLC acquired a new position in shares of Zevra Therapeutics in the 4th quarter worth approximately $133,000. Tidal Investments LLC acquired a new stake in Zevra Therapeutics during the 2nd quarter valued at $150,000. Finally, Quantinno Capital Management LP boosted its stake in Zevra Therapeutics by 114.1% in the first quarter. Quantinno Capital Management LP now owns 32,022 shares of the company’s stock worth $298,000 after purchasing an additional 17,065 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Stock Down 0.6%

NASDAQ:ZVRA opened at $11.32 on Thursday. The stock has a fifty day simple moving average of $11.54 and a 200 day simple moving average of $11.40. The firm has a market capitalization of $672.18 million, a price-to-earnings ratio of 12.30 and a beta of 0.98. Zevra Therapeutics has a 1-year low of $8.01 and a 1-year high of $15.03.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Wednesday, August 5th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.11 by $0.14. The company had revenue of $39.66 million during the quarter, compared to analysts’ expectations of $33.88 million. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 54.54%. Equities analysts predict that Zevra Therapeutics will post 0.72 earnings per share for the current year.

About Zevra Therapeutics

Zevra Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company seeks to address conditions with significant unmet medical needs by combining patient-focused drug development with proprietary technologies designed to improve the delivery and development of medicines.

Zevra’s lead product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children two years of age and older, in combination with miglustat.